Please login to the form below
insulin glargine
This page shows the latest insulin glargine news and features for those working in and with pharma, biotech and healthcare.
Sanofi’s new CEO cuts first deal, adding Synthorx for $2.5bn
Sanofi has had a challenging few years following the loss of patent protection for its former diabetes cash cow Lantus (insulin glargine), with some pipeline successes – notably atopic dermatitis and asthma
Latest news
-
Sanofi said to be looking at options for $30bn consumer health unit
Sanofi has had a difficult few years following the loss of patent protection for its former diabetes cash cow Lantus (insulin glargine), with some pipeline successes – notably atopic dermatitis and asthma
-
Sanofi reveals positive phase 3 results for long-acting insulin Toujeo
Hopes new product can offset continuing decline in franchise. French-drugmaker Sanofi has revealed positive results for its long-acting insulin Toujeo (insulin glargine 300 units/mL), in a study which ... has compared it to Lantus (insulin glargine 100
-
Sanofi exits Zynquista alliance with Lexicon
The Sanofi/Lexicon partnered drug for type 1 diabetes was being co-developed as an add-on therapy to insulin injections to help improve blood sugar control. ... Zynquista was a key element in Sanofi’s plans to rebuild its diabetes franchise following
-
Pricing pressures peg back Lilly’s growth products
The only drug to beat analyst forecasts in the quarter was Basaglar – a biosimilar of Sanofi’s Lantus (insulin glargine) – which grew 51% to $251m.
-
Success for AZ, setback for Sanofi in type 1 diabetes
The decision is a blow to Sanofi’s hopes of rebuilding a diabetes franchise that has been hit the loss of patent protection for big-selling basal insulin Lantus (insulin glargine), ... Analysts have suggested that an oral drug approved as an insulin add
More from news
Approximately 22 fully matching, plus 123 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma leaders to watch in 2020
protection for Lantus (insulin glargine) – as well as cardiovascular disease research.
-
Deal Watch October 2018
agreement for the development and commercialisation of a follow‐on insulin glargine product to Sanofi’s Lantus.
-
Mylan sees the UK paving the way for an insulin game changer
As biosimilars surge into the insulin market, governments are urged to seize ‘the opportunity of the century’. ... Mylan, the global healthcare company, has chosen the UK for the launch pad of its much-anticipated biosimilar version of the Sanofi
-
Going the distance
In fact, its last really big launch was some 14 years ago in the shape of Lantus (insulin glargine), the diabetes blockbuster that is now Sanofi's biggest-selling product. ... Following hot on the heels of Afrezza has been Toujeo (insulin glargine), the
-
Pharma deals during February 2013
Biosimilars continue to attract. Mylan's third Indian deal is in biosimilars, as it sets up an exclusive strategic collaboration with Biocon for three insulin biosimilars: Biocon's Glargine (the generic ... This deal together with the recent option
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest appointments
-
Sanofi promotes diabetes expert Paul Chew to chief medical officer
position. During his time at Sanofi, Dr Chew has been heavily involved in its growing diabetes business, holding responsibility for its long-acting insulin brand Lantus (insulin glargine), and his appointment
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Gilead agrees $21bn buyout of Immunomedics
- Regeneron launches phase 3 COVID-19 antibody trial in the UK
- FDA approves Roche’s Actemra COVID-19 trial
- Roche’s Ocrevus boasts positive long-term data in MS
- First patients dosed with COVID-19 vaccine from SpyBiotech and Serum Institute of India
- Low-dose LSD looks safe for Alzheimer’s patients, but will it work?
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Envision Pharma Group scoops two Silvers at the PM Society Digital Awards 2020
- Alone we can do so little, together we can do so much
- What can't we afford to treat anymore?
- OPEN VIE is awarded a Bronze Award at the PM Society Digital Awards 2020
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
PMHub
An agency called Owen
We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....
Latest intelligence
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
- 7 important considerations for creating an inclusive clinical trial website
- You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Quick links
Infographics
